Literature DB >> 1674840

Impact of age, race, and obesity on hypertensive mechanisms and therapy.

M R Weir1.   

Abstract

Despite the demonstrated efficacy of traditional antihypertensive therapy in reducing blood pressure, hypertension continues to be a major cause of cardiovascular disease morbidity and mortality. Stepped-care therapy is a nonphysiologic approach that, due to potential metabolic derangements and stimulation of undesirable reflex responses, may not substantially reduce the cardiovascular and renal complications associated with hypertension or improve long-term survival in many hypertensive patients. Because of fundamental hemodynamic differences related to the age, race, and weight of hypertensive patients, drug treatment often elicits varying responses. Certain classes of drugs are not only more effective but also more appropriate from a physiologic standpoint in specific types of patients. Therapy selection based in part on hemodynamic mechanisms and demographic patterns is a more rational approach to patient management and may contribute to a better overall outcome than has been observed with conventional treatment.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1674840     DOI: 10.1016/0002-9343(91)90479-h

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  8 in total

1.  1-year stability and prediction of cardiovascular functioning at rest and during laboratory stressors in youth with family histories of essential hypertension.

Authors:  F Treiber; R A Raunikar; H Davis; T Fernandez; M Levy; W B Strong
Journal:  Int J Behav Med       Date:  1994

Review 2.  Stress, stress reduction, and hypertension in African Americans: an updated review.

Authors:  V Barnes; R Schneider; C Alexander; F Staggers
Journal:  J Natl Med Assoc       Date:  1997-07       Impact factor: 1.798

Review 3.  Clinical trials and transethnic pharmacology.

Authors:  M E Kitler
Journal:  Drug Saf       Date:  1994-11       Impact factor: 5.606

4.  Does chocolate reduce blood pressure? A meta-analysis.

Authors:  Karin Ried; Thomas Sullivan; Peter Fakler; Oliver R Frank; Nigel P Stocks
Journal:  BMC Med       Date:  2010-06-28       Impact factor: 8.775

Review 5.  Aldosterone and aldosterone antagonism in systemic hypertension.

Authors:  William H Frishman; Charles T Stier
Journal:  Curr Hypertens Rep       Date:  2004-06       Impact factor: 5.369

6.  Response to six classes of antihypertensive medications by body mass index in a randomized controlled trial.

Authors:  Barry J Materson; David W Williams; Domenic J Reda; William C Cushman
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 May-Jun       Impact factor: 3.738

Review 7.  Treating stage 2 hypertension.

Authors:  Thomas D Giles; Barry J Materson
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-08       Impact factor: 3.738

8.  Difference in blood pressure response to ACE-Inhibitor monotherapy between black and white adults with arterial hypertension: a meta-analysis of 13 clinical trials.

Authors:  Robert N Peck; Luke R Smart; Rita Beier; Anthony C Liwa; Heiner Grosskurth; Daniel W Fitzgerald; Bernhard M W Schmidt
Journal:  BMC Nephrol       Date:  2013-09-26       Impact factor: 2.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.